MRNYYieldMax MRNA Option Income Strategy ETF
Seeks current income and exposure to the share price of Moderna, Inc. (MRNA).
By YieldMax ETFs · Launched 2023
1.00%
#5,189 of 5,854 · expensive
$121M
#2,811 of 5,854 · mid-size
20.82%
2 years
#3,172 of 5,854 · seasoned
Performance
Total-return NAV · USDTotal-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
AlternativeStrategy
Option income
What it actually holds
By weightConcentration
single-stock bet — holdings shown are derivatives collateral, not diversification
Asset allocation
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsYear-on-year price swings
Worst peak-to-trough loss
Needs 3+ years of history
Needs 3+ years of history
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks current income and exposure to the share price of Moderna, Inc. (MRNA).
- Strategy
- Actively managed ETF that seeks current income through a synthetic covered call strategy on MRNA, generating options premiums while providing indirect exposure to MRNA's price returns. The strategy may limit potential gains but aims to capture a portion of MRNA's appreciation.
- Inception date
- October 23, 2023
- Fund family
- YieldMax ETFs
Similar funds
Same asset class, closest by strategy & exposureOur take
Structural notes on how this fund behaves. Read our guide on the 6 warning signs.
The big yield isn't extra money
The headline distribution comes from selling call options, which caps the fund's upside. Across a full market cycle that trade costs more than it brings in — often 1 to 3 percentage points a year against just holding the index. Monthly payouts make the gap easy to miss on a return summary.
A fund-sized fee to own one company
This wraps a single stock, usually with an options overlay on top. You pay 0.50% to 1.00% a year for exposure you could hold directly, and any income comes from selling off your own upside. Owning the share itself costs less and keeps that upside intact.
Sources: Israelov & Ndong, 'A Devil's Bargain: When Generating Income Undermines Investment Returns' (NDVR, 2023) · Israelov & Nielsen, 'Covered Calls Uncovered' (Financial Analysts Journal 2015)
Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More
What's next?
You've looked at MRNY. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.
Data updated on 2026-08-03